S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:PODD - Insulet Stock Price, Forecast & News

$191.20
+0.25 (+0.13 %)
(As of 01/23/2020 04:00 PM ET)
Today's Range
$190.67
Now: $191.20
$193.39
50-Day Range
$169.34
MA: $178.22
$191.39
52-Week Range
$73.90
Now: $191.20
$193.39
Volume263,300 shs
Average Volume499,276 shs
Market Capitalization$11.82 billion
P/E Ratio735.41
Dividend YieldN/A
Beta1
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.32 per share
Book Value$3.59 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$11.82 billion
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by $0.02. The medical instruments supplier had revenue of $192.12 million for the quarter, compared to analyst estimates of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. The business's revenue for the quarter was up 27.2% on a year-over-year basis. During the same period last year, the company posted $0.03 earnings per share. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for PODD?

17 brokers have issued 1 year price targets for Insulet's shares. Their forecasts range from $100.00 to $200.00. On average, they anticipate Insulet's stock price to reach $158.82 in the next year. This suggests that the stock has a possible downside of 16.9%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

Media coverage about PODD stock has trended somewhat positive recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Insulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), Tandem Diabetes Care (TNDM), Splunk (SPLK), salesforce.com (CRM), Veeva Systems (VEEV), Roku (ROKU) and Adobe (ADBE).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include KAMES CAPITAL plc (0.55%), Ambassador Advisors LLC (0.09%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Calamos Advisors LLC (0.02%), Tributary Capital Management LLC (0.02%) and First Hawaiian Bank (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Ambassador Advisors LLC, KAMES CAPITAL plc, Tocqueville Asset Management L.P. and Tributary Capital Management LLC. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , Polianta Ltd, IFM Investors Pty Ltd, Sciencast Management LP, Alpine Global Management LLC, First Hawaiian Bank and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $191.20.

How big of a company is Insulet?

Insulet has a market capitalization of $11.82 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  615 (Vote Outperform)
Underperform Votes:  540 (Vote Underperform)
Total Votes:  1,155
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel